Point radiopharma drug results disappoint in prostate cancer study
Bio Pharma Dive
DECEMBER 18, 2023
While the study met its goal, the drug’s benefit was less than analysts had predicted, an outcome that could hasten a planned takeover by Eli Lilly.
Mon.Dec 18, 2023
189 
Vertex secures CHMP nod for Casgevy approval in Europe
Pharmaceutical Technology
DECEMBER 18, 2023
Following US and UK approvals, the EMA’s CHMP has recommended conditional approval for Casgevy, with a decision expected in Q1 2024.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
A Dentist Reveals What Happens to Your Teeth as You Get Older
AuroBlog - Aurous Healthcare Clinical Trials blog
DECEMBER 18, 2023
A healthy smile helps us live long, well and happy lives. But just like our bodies, our teeth succumb to age-related changes. So what happens to teeth as you age? And what can you do to ensure your smile lasts the distance? [link] First, what are teeth made of?
Novo Nordisk Foundation sets up airborne infection vaccine initiative
Pharmaceutical Technology
DECEMBER 18, 2023
The Novo Nordisk Foundation has invested Dkr1.8bn in the initiative to develop vaccines for various airborne infection diseases.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pivotal Life Sciences reloads with $389M, hunting for deals in a downturn
Bio Pharma Dive
DECEMBER 18, 2023
The firm is tracking startups that launched during the biotechnology sector’s peak a few years ago but now need fresh funds to move their programs forward, one of its investors said.
Experts prefer whole genome sequencing as viable option to identify & characterize bacteria as concerns of AMR escalate
AuroBlog - Aurous Healthcare Clinical Trials blog
DECEMBER 18, 2023
As antimicrobial resistance (AMR) poses a growing threat to global public health, challenging the effectiveness of antibiotics and other antimicrobial drugs, medical experts suggest whole genome sequencing as a viable option to identify and characterize the bacteria, viruses, fungi or parasites, along with their transmission pattern.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Cognitive decline in early Alzheimer’s could stem from serotonin loss
Pharma Times
DECEMBER 18, 2023
MCI patients had 25% lower levels of serotonin compared to healthy patients - News - PharmaTimes
Foundation behind Novo Nordisk to invest $260M in vaccine R&D
Bio Pharma Dive
DECEMBER 18, 2023
The newly established initiative, which consists of a research center and an accelerator, will focus on developing vaccines for tuberculosis, influenza and group A streptococcus.
Digital health collaboration to trial AI-powered X-rays for lung cancer detection
Pharma Times
DECEMBER 18, 2023
Earlier diagnosis could increase patient survival rates by five years or more - News - PharmaTimes
Illumina to part with Grail, ending battle with regulators
Bio Pharma Dive
DECEMBER 18, 2023
Activist investor Carl Icahn, who is suing the company over its acquisition of Grail, continued to push for the removal of several board members in a letter to fellow shareholders.
Pharmaceutical Technology’s most-read stories of 2023
Pharmaceutical Technology
DECEMBER 18, 2023
Our most popular stories of the year involve CRISPR therapies, generative AI, obesity drugs entering prime time, and changes in the Covid-19 landscape, signaling the biggest trends in the pharmaceutical and biotech industry.
December 18, 2023: Ethics Consultation Documents Now Available for ARBOR-Telehealth and I CAN DO Surgical ACP
Rethinking Clinical Trials
DECEMBER 18, 2023
Ethics and regulatory onboarding documentation for 2 of the NIH Pragmatic Trials Collaboratory's newest trials is now available. The documents include meeting minutes and supplementary materials summarizing recent discussions of ethics and regulatory issues associated with the ARBOR-Telehealth and I CAN DO Surgical ACP studies. The consultations took place by video conference and included representation from the studies' principal investigators, members of the NIH Collaboratory's Ethics and Regu
Pivotal bioVenture raises the stakes in biotech and pharmaceutical support
Pharmaceutical Technology
DECEMBER 18, 2023
The latest $389m pledge follows an initial investment of $300m in 2017 that was raised to fund early-stage life-science startups.
To fight rare diseases, win the data battle first
pharmaphorum
DECEMBER 18, 2023
To effectively combat rare diseases, it is essential to prioritise the collection and analysis of data. This article explores how pharmaceutical companies are leveraging AI and focusing on orphan drugs to tackle rare diseases.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Magazine: Advancing islet transplantation for type 1 diabetes
Pharmaceutical Technology
DECEMBER 18, 2023
In this issue: Diabetes researchers oppose the regulation of islet transplantation as a biologic in the US, why haemophilia gene therapies are so expensive, how AI will help with trial recruitment.
Bristol Myers Squibb's Opdualag comes up short in late-stage colorectal cancer trial
Fierce Pharma
DECEMBER 18, 2023
Bristol Myers Squibb’s PD-1/LAG3 combo Opdualag has more than proved its worth in melanoma since its first-in-class approval in 2022. | The company opted to cut the phase 3 Relativity-123 study after an analysis found that the trial was unlikely to achieve its primary endpoints in microsatellite-stable patients with metastatic colorectal cancer.
Illumina to divest Grail after two years of lawsuits
Pharmaceutical Technology
DECEMBER 18, 2023
Illumina aims to finalise the terms of this divestiture by the end of the second quarter of 2024.
GSK tees up AstraZeneca rivalry with positive Jemperli-Zejula readout in endometrial cancer
Fierce Pharma
DECEMBER 18, 2023
On a mission to grow in oncology, GSK has more positive data to report in endometrial cancer. | GSK has more positive data to report in endometrial cancer as the company's PD-1/PARP combination turned in a trial win. The combination could represent a threat to a rival therapy at AstraZeneca.
Biocytogen and Ona enter cancer ADC development deal
Pharmaceutical Technology
DECEMBER 18, 2023
Biocytogen Pharmaceuticals and Ona Therapeutics signed an antibody agreement to develop antibody-drug conjugates for solid tumours.
Charles River snags clearance to produce Vertex and CRISPR's Casgevy from Tennessee plant
Fierce Pharma
DECEMBER 18, 2023
Following a string of approvals in the United States and beyond, Vertex Pharmaceuticals continues to build out its manufacturing network for the world’s first CRISPR-based gene therapy, Casgevy.
CymaBay seeks FDA approval for primary biliary cholangitis therapy
Pharmaceutical Technology
DECEMBER 18, 2023
CymaBay Therapeutics has filed a new drug application (NDA) with the FDA seeking approval for seladelpar for PBC management.
Illumina admits defeat in Grail quest, opting to divest
pharmaphorum
DECEMBER 18, 2023
Illumina will divest cancer detection company Grail after losing an appeal in an antitrust court case in the US
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
FDA backs Astellas-Pfizer’s Padcev with Keytruda for urothelial cancer
Pharmaceutical Technology
DECEMBER 18, 2023
The US FDA approved Astellas Pharma-Pfizer’s Padcev plus Merck’s (MSD) Keytruda to treat locally advanced or metastatic urothelial cancer.
Eisai files biliary tract cancer drug tasurgratinib in Japan
pharmaphorum
DECEMBER 18, 2023
Eisai files for approval in Japan for FGFR inhibitor tasurgratinib as a treatment for biliary tract cancers with FGFR2 gene fusions
EMA CHMP recommends Takeda’s Hyqvia for CIDP treatment
Pharmaceutical Technology
DECEMBER 18, 2023
The EMA CHMP recommended granting approval for Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy.
Organon pays $50M upfront to pick up rights to pair of Eli Lilly migraine meds in Europe
Fierce Pharma
DECEMBER 18, 2023
Organon, the women's health-focused spinoff of Merck, has picked up the rights to distribute and promote a pair of migraine medicines overseas. | Organon has unveiled a pact with Eli Lilly to take charge of Emgality and Rayvow marketing in Europe. Emgality is approved to help prevent migraines in adults who have at least four migraine days per month, while Rayvow is cleared for acute treatment of the headache phase of migraine attacks.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Cognitive decline in early Alzheimer’s could stem from serotonin loss
Pharma Times
DECEMBER 18, 2023
MCI patients had 25% lower levels of serotonin compared to healthy patients Researchers from Johns Hopkins Medicine have suggested that serotonin loss in parts of the brain may play a role in cognitive decline in the early stages of Alzheimer’s disease (AD). Published in the Journal of Alzheimer’s Disease , the study was supported by other contributing scientists from the Johns Hopkins University School of Medicine and the Johns Hopkins Bloomberg School of Public Health.
CHMP backs Biogen’s Skyclarys for Friedreich’s ataxia
pharmaphorum
DECEMBER 18, 2023
Biogen’s Skyclarys is on course to becoming the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU after it was recommended by the EMA’s human medicines committee.
New patent expiration for Glaxosmithkline drug VENTOLIN HFA
Drug Patent Watch
DECEMBER 18, 2023
Annual Drug Patent Expirations for VENTOLIN+HFA Ventolin Hfa is a drug marketed by Glaxosmithkline and is included in one NDA. It is available from nine suppliers. There are two patents… The post New patent expiration for Glaxosmithkline drug VENTOLIN HFA appeared first on DrugPatentWatch - Make Better Decisions.
New RUBY readout buoys GSK’s Jemperli in endometrial cancer
pharmaphorum
DECEMBER 18, 2023
RUBY Part 2 trial of GSK's PD-1 inhibitor Jemperli and PARP inhibitor Zejula could open up wider use in first-line endometrial cancer
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content